Engineered immune cells take on tough blood disorder
NCT ID NCT07530380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment for people with a severe type of autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy the faulty B cells causing the disease. The main goals are to check safety and see if the therapy can control the anemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - WARM AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Hospital of Anhui Medical University
RECRUITINGHefei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- Engineered immune cells take on rare blood disorders
- Brain scans reveal hidden thinking problems in anemia patients
- Experimental immune therapy for stubborn anemia shows early promise but trial stalls
- Experimental CAR-T therapy takes on stubborn blood disorder